pediatric AML – Medxy AI

Mitochondrial Transfer via Tunneling Nanotubes: A Novel Mechanism of Macrophage-Mediated Immunosuppression in Pediatric AML

By MedXY 10/19/2026

Mitochondrial transfer from pediatric AML blasts to macrophages via tunneling nanotubes induces metabolic and immunosuppressive reprogramming, impairing anti-leukemic immune responses and supporting chemoresistance, revealing potential targets to enhance immunotherapy efficacy.

Hematology-Oncology news Pediatrics

Navigating Therapeutic Approaches in Pediatric Relapsed Acute Myeloid Leukemia: Current Trends and Comparative Outcomes

By MedXY 09/03/2026

This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall survival.

Hematology-Oncology news Pediatrics

Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact

By MedXY 10/14/2025

MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.